Open in interactive viewer → charts, metric popovers & call review

Ascend Hits 61 Stores, Prints Positive Cash Flow — and the Stock Is Down 47% From Its September High

The cannabis operator's Q3 was its best operational quarter in years. The tape, the balance sheet, and a hemp deadline that moved again tell a more guarded story.
AAWH · Earnings Call · 2026-11-12

Ascend Wellness reported on November 12 and, by management's telling, this was the quarter the strategy finally printed. Revenue of $130 million, up 3.1% sequentially and 4.2% year-over-year. Adjusted EBITDA of $31.1 million at a 23.9% margin, 80 basis points better than Q2. The 60-store target reached early — 61 doors including partner locations, up from 39 just over two years ago. And cash flow from operations positive despite a $19.1 million biannual interest payment that landed in July.

The stock, meanwhile, is down 21% over the last 90 trading days and 47% from its September 29 high of $0.64, on a market cap of roughly $68 million. That gap — between the operating story being told and the price being paid — is the whole dossier.

The Growth Arc, Audited

The headline is a return to year-over-year growth, and that word is doing work. Total revenue peaked at $141 million in Q3 2024 and sagged to $117 million by Q1 2026 before the last two quarters rebuilt it to $126 million and then $130 million. So the sequential streak is real, but it's a recovery from a trough, not an acceleration from a high. Operating income remains deeply negative, and the whole equity is priced at about a fifth of sales. Price to revenue of 0.2x tells you the market is not paying for the recovery yet.

Also worth flagging on quality of earnings: the analyst on the call, Kenric Tyghe, went straight at the G&A step-up. CFO Roman Nemchenko was candid — “the largest sequential increase really had to do with the incentive comp accrual. So we did take a $2 million charge in Q3 that was substantially less in Q2.” — Roman Nemchenko, CFO · 2026-11-12 That's a conservative accrual inside a 23.9% margin, not a flattered one. Credit where due.

Wholesale: Strategy or Surrender?

Here is the most interesting tension on the call. Wholesale revenue fell 3.6% sequentially to $32.2 million, and the CEO's framing was that this is deliberate:

The wholesale decline is not, if you look at the BDSA rankings of our products, we are selling more products than we ever have in our history. And it's just moving from the wholesale channel to the retail channel...

Samuel Brill, CEO · 2026-11-12

That is a coherent argument — vertical retail captures more margin per gram than wholesale, and the mix shift shows up in gross profit. But note what has quietly left the conversation. Wholesale revenue was one of the company's biggest keyword gainers back in 2022, and wholesale channel ranked near the top of the keyword set in late 2024. It doesn't appear anywhere in the current top-30. A theme management spent years promoting has been conceptually retired, replaced by retail densification and core markets — core markets being the Illinois/New Jersey/Massachusetts/Ohio hub where the fixed-cost leverage supposedly bites.

And the analyst didn't buy the reconciliation cleanly. Asked to square 10% door growth with a 1%–2% Q4 revenue guide, Tyghe pushed twice. The CEO's answer was essentially promotional seasonality: “People get extremely promotional in the fourth quarter, especially with wholesale as the year ends... we've seen this year after year.” — Samuel Brill, CEO · 2026-11-12 Fair. But price compression is the company's number-one keyword this quarter — it was also number one in Q1 2025. This is a chronic condition, not a new headwind. The return to growth is happening despite it, which is the bullish read; the bearish read is that new doors are being swallowed by falling prices, which is exactly what a 1%–2% guide against 10% unit growth implies.

The Hemp Unlock That Keeps Moving

The regulatory option is the second thread. The federal deadline to close the intoxicating hemp loophole slipped from November 12 to December 11 — the keyword intoxicating hemp sits near the top of the company's theme list, and federal deadline entered the set this quarter.

Compare with what management said three months ago: “the hemp ban, I guess, is not scheduled to take place until late Q4. So I'm not sure we're going to get a tailwind from that.” — Samuel Brill, CEO · 2026-08-12 Then, on the same call, the size of the prize: a total hemp market “somewhere in the $20 billion, $30 billion range.” — Samuel Brill, CEO · 2026-08-12 This quarter the language firmed up — “When those products come off the shelves, we expect a meaningful share of that demand to move into the regulated market.” — Samuel Brill, CEO · 2026-11-12 But the guide is telling: 1%–2% Q4 growth with no hemp benefit baked in. The catalyst has now been deferred repeatedly, and the company has stopped underwriting it. That's the honest posture — and it means the option is free in the equity.

One genuinely new datapoint: Massachusetts voters rejected adult-use repeal with more than 75% voting no. The CEO called it nearly impossible to get 75% of voters to agree on anything. A durable-demand signal in a core market, and a keyword (voters) that spiked this quarter.

Capital: The Quiet Constraint

The reason a good quarter gets sold is the balance sheet. Effective net cash of negative $293 million, with liabilities at 109.6% of assets. The $11 million mortgage at 8.5%, secured on five properties, was described as lower-cost, non-dilutive capital; in the Q&A the CEO called it a much lower cost of capital — which tells you what the existing stack costs. The reverse split approved August 28 exists to enable an eventual major-exchange uplisting, another keyword that surfaced last quarter and has gone quiet since.

What holds it together is the M&A pipeline and the return math. “the number I quoted last quarter was we were getting north of 30% return on invested capital. That is a very high bar, I think, in any industry.” — Samuel Brill, CEO · 2026-11-12 If distressed single-store acquisitions really clear 30%+ including synergies, buying doors with non-dilutive property debt is the right capital allocation in a consolidating, price-compressed market. If they don't, the leverage does the talking.

Two smaller notes. International is brand new: a licensing deal with a Canadian craft cannabis producer to bring High Wired and Ozone vapes north — and refreshingly un-hyped: “honestly it was not something that we were seeking.” — Samuel Brill, CEO · 2026-11-12 And loyalty members now drive 86% of transactions, the real engine behind the same-store-decline narrowing.

What the Market Is Pricing

The operating story is credible and improving: margin up, cash positive through an interest payment, doors compounding, gross profit mix shifting toward retail. The equity story is being held hostage by three things — 110% liabilities-to-assets, a hemp catalyst that keeps sliding, and a price environment where 10% more doors produces 1%–2% more revenue. Management is doing the right thing by not guiding the hemp tailwind; investors are doing the rational thing by not paying for it either. The next 90 days are a bet on whether December 11 finally means something.